| Study |
Time |
Treatment group |
Outcome |
No. improved |
No. of pts |
Risk (%) |
Risk Difference |
NNT |
| Creamer 1994 |
1‐4 wk |
T: Hyalgan |
Number of joints without night pain |
7 |
12 |
58 |
16 |
6.3 |
| |
|
C: Saline |
|
5 |
12 |
42 |
|
|
| Creamer 1994 |
5‐13 wk |
T: Hyalgan |
Number of joints without night pain |
7 |
12 |
58 |
16 |
6.3 |
| |
|
C: Saline |
|
5 |
12 |
42 |
|
|
| Creamer 1994 |
1‐4 wk |
T: Hyalgan |
Number of joints without rest pain |
6 |
12 |
50 |
8 |
12.5 |
| |
|
C: Saline |
|
5 |
12 |
42 |
|
|
| Creamer 1994 |
5‐13 wk |
T: Hyalgan |
Number of joints without rest pain |
5 |
12 |
42 |
25 |
4 |
| |
|
C: Saline |
|
2 |
12 |
17 |
|
|
| Grecomoro 1987 |
1 wk |
T: Hyalgan |
Number of joints with improvement in pain under load/walking |
16 |
20 |
80 |
58 |
1.7 |
| |
|
C: Phosphate buffer |
|
4 |
18 |
22 |
|
|
| Grecomoro 1987 |
1 wk |
T: Hyalgan |
Number of joints with improvement on pain on touch |
15 |
20 |
75 |
42 |
2.4 |
| |
|
C: Phosphate buffer |
|
6 |
18 |
33 |
|
|
| Altman 1998 |
14‐26 wk |
T: Hyalgan |
Number of patients with moderate/marked pain |
36 |
105 |
34 |
‐12 |
‐8.3 |
| |
|
C: Saline |
|
53 |
115 |
46 |
|
|
| Corrado 1995 |
1‐4 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
6 |
19 |
32 |
‐43 |
‐2.3 |
| |
|
C: Saline |
|
12 |
16 |
75 |
|
|
| Creamer 1994 |
1‐4 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
5 |
12 |
42 |
9 |
11.1 |
| |
|
C: Saline |
|
4 |
12 |
33 |
|
|
| Formiguera Sala 1995 |
1‐4 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
8 |
20 |
40 |
‐15 |
‐6.7 |
| |
|
C: Saline |
|
11 |
20 |
55 |
|
|
| Corrado 1995 |
5‐13 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
14 |
19 |
74 |
‐1 |
‐10 |
| |
|
C: Saline |
|
12 |
16 |
75 |
|
|
| Formiguera Sala 1995 |
5‐13 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
6 |
20 |
30 |
‐35 |
‐2.9 |
| |
|
C: Saline |
|
13 |
20 |
65 |
|
|
| Henderson 1994 |
14‐26 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
17 |
40 |
43 |
4 |
25 |
| |
|
C: Saline |
|
17 |
44 |
39 |
|
|
| Huskisson 1999 |
14‐26 wk |
T: Hyalgan |
Patient global assessment (number of patients improved) |
10 |
40 |
25 |
‐32 |
‐3.1 |
| |
|
C: Saline |
|
22 |
41 |
57 |
|
|
| Dougados 1993 |
45‐52 wk |
T: Hyalectin |
Number of patients rating treatment effective |
31 |
47 |
66 |
‐10 |
‐10 |
| |
|
C: Saline |
|
27 |
48 |
56 |
|
|
| Bragantini 1987 |
5‐13 wk |
T: Hyalgan |
Number of joints fairly good, good, very good |
2 |
19 |
11 |
‐56 |
‐1.8 |
| |
|
C: Saline |
|
12 |
18 |
67 |
|
|
| Creamer 1994 |
5‐13 wk |
T: Hyalgan |
Number of joints fairly good, good, very good |
5 |
12 |
42 |
9 |
11.1 |
| |
|
C: Saline |
|
4 |
12 |
33 |
|
|
| Jubb 2003 |
5‐13 wk |
T: Hyalgan |
Pain (number of patients improved) |
88 |
208 |
42 |
6 |
16.7 |
| |
|
C: Saline |
|
71 |
200 |
36 |
|
|
| Jubb 2003 |
32 wk |
T: Hyalgan |
Pain (number of patients improved) |
92 |
208 |
44 |
11 |
9.1 |
| |
|
C: Saline |
|
65 |
200 |
33 |
|
|
| Bragantini 1987 |
End of treatment |
T: Hyalgan |
Number of joints improved in walking pain |
16 |
19 |
84 |
34 |
2.9 |
| |
|
C: Saline |
|
9 |
18 |
50 |
|
|
| Bragantini 1987 |
5‐13 wk |
T: Hyalgan |
Number of joints improved in walking pain |
17 |
19 |
89 |
50 |
2 |
| |
|
C: Saline |
|
7 |
18 |
39 |
|
|
| Grecomoro 1987 |
1 wk |
T: Hyalgan |
Number of joints improved in walking pain |
16 |
20 |
80 |
58 |
1.7 |
| |
|
C: Phosphate buffer |
|
4 |
18 |
22 |
|
|
| Bragantini 1987 |
End of treatment |
T: Hyalgan |
Number of joints with improvement in pain under load |
6 |
18 |
33 |
‐56 |
‐1.8 |
| |
|
C: Saline |
|
17 |
19 |
89 |
|
|
| Bragantini 1987 |
5‐13 wk |
T: Hyalgan |
Number of joints with improvement in pain under load |
4 |
18 |
22 |
‐67 |
‐1.5 |
| |
|
C: Saline |
|
17 |
19 |
89 |
|
|
